Compare IHRT & CYPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IHRT | CYPH |
|---|---|---|
| Founded | 1974 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 284.8M | 321.1M |
| IPO Year | 2019 | 2019 |
| Metric | IHRT | CYPH |
|---|---|---|
| Price | $0.58 | $1.92 |
| Analyst Decision | Sell | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $0.88 | N/A |
| AVG Volume (30 Days) | 3.5M | ★ 13.3M |
| Earning Date | 11-09-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 54.19 | ★ 103.87 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,864,991,000.00 | $1,500,000.00 |
| Revenue This Year | $5.60 | N/A |
| Revenue Next Year | $0.45 | $408.92 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 0.27 | N/A |
| 52 Week Low | $0.56 | $0.49 |
| 52 Week High | $6.56 | $4.19 |
| Indicator | IHRT | CYPH |
|---|---|---|
| Relative Strength Index (RSI) | 24.90 | 39.82 |
| Support Level | N/A | $0.65 |
| Resistance Level | $2.34 | $3.42 |
| Average True Range (ATR) | 0.21 | 0.36 |
| MACD | -0.12 | -0.11 |
| Stochastic Oscillator | 3.00 | 12.96 |
iHeartMedia Inc is a United States-based audio media company. The company operates through the segments of the Multiplatform Group, the Digital Audio Group, and the Audio & Media Services Group. The company derives prime revenue from the Multiplatform Group segment which includes the company's Broadcast radio, Networks and Sponsorships, and Events businesses. The Digital Audio Group segment includes all of the company's digital businesses, including podcasting; and the Audio & Media Services Group includes Katz Media Group, a full-service media representation business, and RCS Sound Software, a provider of scheduling and broadcast software and services.
Cypherpunk Technologies Inc is a privacy technology company focused on implementing a digital asset treasury business anchored by Zcash, which is a cryptographic digital asset that operates on a decentralized, open-source blockchain network known as the Zcash Network. Through its subsidiary, the company is also engaged in developing novel therapies for patients with cancer. The group holds Zcash as part of its digital treasury business and has the following drug candidates under development in its biopharma business: Sirexatamab (DKN-01), a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1; and a preclinical antibody program, FL-501, that is designed to treat cachexia-related indications.